RadNet, Inc. (RDNT)
NEGATIVEFondamental
35
Prix
$76.22
Capitalisation boursière
$5.92B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretations of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$2.27B
12 derniers mois (au 30/06/2026)
Résultat net
$-21M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
-
Capitaux propres totaux
$1.09B
Passif total
$2.40B
Ratio de liquidité général
1.48
Couverture des intérêts
0.99
Dette/EBITDA
10.20
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$52.45
Prix actuel
$76.22
Marge de sécurité
-45.3%
Fourchette de juste valeur
$34.09 - $70.81
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-1.7%
Ratio P/B
5.36
P/FCF
-
Marge brute
-
ROIC
1.6%
Radar de rentabilité
Value Creation (Economic Moat)
ROIC
1.6%
WACC
9.7%
ROIC − WACC
-8.1 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critères d'analyse fondamentale
Réussi (6)
- Price CAGR 28.12%
- Debt/Equity ratio
- Current Ratio
- Revenue Growth 5Y 13.7%
- Analyst Consensus 93% Buy
- Earnings Surprise avg 13.4%
Échoué (13)
- EPS shows upward trend
- ROIC 1.6%
- P/B Ratio 5.36
- Operating Margin 3.1%
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Overvalued)
- ROE -1.4%
- Share Dilution 6.8%
- Net Margin Trend -0.9% vs -0.8%
- Piotroski F-Score 3/9
Indisponible (8)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Score F de Piotroski
Préoccupations financières sérieuses
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Émission de nouvelles actions, diluant la participation
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Dr. Howard G. Berger M.D. | Chairman, President & CEO | 79 |
| Mr. Mark D. Stolper | Executive VP & CFO | 54 |
| Mr. Mital Patel | Executive VP & COO | 39 |
| Mr. Norman R. Hames | President & CEO of Western Operations | 69 |
| Mr. Stephen M. Forthuber | President & CEO of Eastern Operations | 64 |
| Dr. Alma Gregory Sorensen M.D. | Executive VP, Chief Strategy Officer & Director | 63 |
| Ms. Susan Hollabaugh | Chief Information Officer | - |
| Mr. David Jeffrey Katz Esq. | Executive VP, Chief Legal Officer & Corporate Secretary | 61 |
| Mr. David Manheim | Senior VP & Chief Compliance Officer | - |
| Mr. Michael M. Murdock | Executive Vice President of Mergers & Acquisitions | 70 |
Risque d'audit
8
Risque du conseil
8
Risque de rémunération
7
Risque droits des actionnaires
2
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Latest News
Recent headlines for RDNT, sourced from Markets Gazette.
- 3/2/2026NEUTRALRadNet (RDNT) Q4 2025 Earnings Call Transcript
The transcript for RadNet Inc.'s (RDNT) Q4 2025 earnings call is now available to investors. While access to such documents is crucial for understanding the company's financial performance and future outlook, the current lack of specific content details prevents an immediate assessment of market impact. Analysts and investors are awaiting a review of key data, management statements, and projections to evaluate RadNet's operational and strategic health. Earnings calls are pivotal moments for grasping growth trends, profit margins, and any potential challenges the company might face in the diagnostic imaging services sector. Without the content, the signal remains neutral, pending further insights.
- 3/2/2026NEUTRALRadNet Earnings Review: Q4 Summary
Markets Gazette notes the announcement of RadNet's Q4 earnings review. While the title suggests an upcoming analysis of the company's financial performance, the provided article lacks specific details regarding the results, such as revenue figures, earnings per share, or future projections. This absence of concrete data prevents investors from assessing RadNet's current financial health or anticipating potential market movements. Traders are eagerly awaiting further information to formulate informed investment strategies.
via Markets Gazette